Navigation Links
Presentation of North America's First Certificate for BS 25999, the New Standard for Business Continuity

RESTON, Va., July 8 /PRNewswire/ -- BSI announced today that Repligen Corporation, Waltham, MA (Nasdaq: RGEN); the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, the fastest growing segment of the biopharmaceutical industry has achieved BS 25999 certification. Repligen is the first company in North America to have achieved certification for their commitment to ensuring business continuity in the event of disaster or disruption.

BS 25999 is a visionary standard designed to keep your business going during the most challenging and unexpected circumstances. It provides a basis for understanding, developing, implementing and managing business continuity within your organization and gives you confidence when dealing with stakeholders both within and outside your organization. BS 25999 is an auditable standard which means that through certification, you have a framework for continual improvement and the ability to demonstrate to your stakeholders that your BCM program meets globally accepted best practice.

"By earning BS 25999 certification, Repligen is clearly demonstrating their commitment to ensure continued operation in the face of any potential cause of business disruption," said Gary Pearsons, President of BSI Management Systems. "Repligen is the first company in North America to achieve BS 25999 certification. This is just one more example of the leadership role Repligen has earned in their industry. Through the combined strength of Repligen implementing a disciplined management system and BSI providing independent verification and certification; Repligen's stakeholders and customers can be assured of the resiliency of their operations."

"Repligen is at the head of a long and growing list of leading-edge companies wishing to prove that they are doing what is required to protect their businesses, their stakeholders, and their customers," Pearsons added.

"As the world's leading supplier of recombinant Protein A, we felt that it was important to be on the cutting edge of business continuity to ensure an uninterrupted supply of products to our customers and ultimately to patients," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Implementation of and certification to BS 25999 has helped Repligen become more resilient, and agile by providing valuable insight into the issues and challenges that we may face in the event of a business interruption. We are very proud to be the first company in North America to have gained certification."

Media information

Shereen Abuzobaa

VP Marketing

BSI Management Systems



About BSI Management Systems

BSI Management Systems is one of the world's largest certification bodies, with over 60,000 certified locations and clients in more than 100 countries. Operating through a global network, BSI Management Systems provides assessment, certification and training services in all critical areas of management disciplines including:

-- Business Continuity

-- Environment

-- Food Safety

-- Health & Safety

-- Information Security

-- Integrated Management

-- Quality

-- Social Accountability

-- Sustainable Development

-- IT Service Management

About Repligen and Recombinant Protein A

Repligen is the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies. There are approximately 20 monoclonal antibodies that have received regulatory approval with more than 200 products in various stages of clinical development. The worldwide revenues from this class of drug exceeded $20 billion in 2006 and are forecast to exceed $30 billion in 2010. Monoclonal antibodies are the largest and fastest growing class of drug in the biopharmaceutical industry. (

SOURCE BSI Management Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL Announces Investor Relations Presentation Available on Website
2. deCODE genetics to Webcast Presentations at Annual R&D Event
3. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
4. deCODE genetics to Webcast Presentation at Piper Jaffray Europe Conference
5. Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference
6. Gen-Probe to Webcast Presentation at the William Blair & Company 28th Annual Growth Stock Conference
7. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
8. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
11. Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocepts I.D.Rh(D) Prenatal Diagnostic
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Pittcon is pleased to announce the 2016 ... symposia, oral sessions, workshops, awards, and posters. The core of the Technical ... as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food science, fuels/energy, ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):